<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04244396</url>
  </required_header>
  <id_info>
    <org_study_id>ABT-CIP-10295</org_study_id>
    <nct_id>NCT04244396</nct_id>
  </id_info>
  <brief_title>Persistent Atrial Fibrillation (AF) (Asia Pacific) Observational Study</brief_title>
  <acronym>PerAF APAC</acronym>
  <official_title>Persistent AF (Asia Pacific) Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this clinical trial is to collect safety and effectiveness data for the
      TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath SE) in the APAC
      patient population for the treatment of drug refractory, symptomatic persistent atrial
      fibrillation when following standard electrophysiology mapping and radiofrequency (RF)
      ablation procedures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The PerAF APAC trial is a prospective, single arm, non-randomized, observational, post-market
      clinical investigation. Approximately 100 subjects will be enrolled at up to 15 sites in
      South Korea, Singapore, Hong Kong, Taiwan, and India. Centers in other countries within APAC
      may be approached for participation in the clinical investigation as needed. Subjects will be
      followed for 15-months after their initial ablation procedure. The primary effectiveness and
      safety endpoints will be evaluated through 15-months. A core lab will independently assess
      AF/AFL/AT recurrence via Holter monitoring at the 6-month and 15-month follow-up visits. All
      serious adverse events (SAEs) will be independently adjudicated by qualified physicians not
      participating in the trial
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 25, 2020</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from AF/atrial flutter (AFL)/atrial tachycardia (AT) episodes of &gt;30 seconds in duration</measure>
    <time_frame>through 15-months</time_frame>
    <description>AF/AFL/AT is defined as episodes of &gt;30 seconds</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of device and/or procedure-related serious adverse events</measure>
    <time_frame>7-days</time_frame>
    <description>device and/or procedure-related serious adverse events are pre-defined as below with onset within 7-days of any ablation procedure that uses the TactiCath SE catheter
Atrioesophageal fistula - assessed through 15 months
Cardiac tamponade/perforation - assessed through 15 months
Death
Heart block
Myocardial infarction (MI)
Pericarditis - pleuritic symptoms &gt;7 days and/or requires hospitalization &gt;24 hrs for reasons other than observational purposes only
Phrenic nerve injury resulting in diaphragmatic paralysis
Pneumothorax
Pulmonary edema (respiratory insufficiency)
Pulmonary vein stenosis - assessed through 15 months
Stroke/cerebrovascular accident
Thromboembolism
Transient ischemic attack
Vascular access complications (including major bleeding events)</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Persistent Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Drug refractory, symptomatic persistent atrial fibrillation</arm_group_label>
    <description>Asian population</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath SE)</intervention_name>
    <description>TactiCath SE is indicated for use in cardiac electrophysiological mapping (stimulation and recording), and, when used in conjunction with a radiofrequency generator, for cardiac ablation of supraventricular arrhythmias in the right and left atrium, including atrial fibrillation.</description>
    <arm_group_label>Drug refractory, symptomatic persistent atrial fibrillation</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This clinical investigation will enroll drug refractory, symptomatic, persistent atrial
        fibrillation (AF) subjects who will undergo a de novo RF ablation procedure. Subjects must
        provide written informed consent prior to conducting any investigation-specific procedures
        not considered standard of care.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent

          2. Documented symptomatic persistent AF, defined as continuous AF sustained &gt;7-days but
             &lt;1 year documented by:

               1. Physician's note AND one of the following:

               2. 24-hr Holter showing continuous AF within 90-days of the procedure OR

               3. 2 ECGs (from any form of rhythm monitoring) showing continuous AF, taken at least
                  7-days apart

          3. Refractory or intolerant to at least one Class I or III antiarrhythmic drug (AAD) as
             evidenced by recurrent symptomatic AF NOTE: Intolerant = unable, unwilling, or refusal
             to take AADs

          4. ≥18 years of age

          5. Able and willing to complete all pre-, post-, and follow-up testing and requirements

        Exclusion Criteria:

          1. Continuous AF &gt;12 months.

          2. Previous left atrial (LA) surgical or catheter ablation for AF

          3. Any cardiac procedure within 90-days prior to procedure (Diagnostic procedures with no
             intervention are not considered a surgical or percutaneous surgical procedure)

          4. Coronary artery bypass graft (CABG) surgery within 6-months prior to procedure

          5. Valvular cardiac surgical/percutaneous procedure

          6. Any carotid stenting or endarterectomy

          7. Documented LA thrombus on imaging

          8. LA diameter &gt;50 mm

          9. Left Ventricular Ejection Fraction (LVEF) &lt;40%

         10. Unable to take anticoagulation medication

         11. History of blood clotting or bleeding abnormalities

         12. Myocardial Infarction (MI), acute coronary syndrome, Percutaneous coronary
             intervention (PCI) within the 3-mos prior to the procedure

         13. Documented thromboembolic event within 12-months prior to the procedure

         14. Rheumatic heart disease

         15. Uncontrolled heart failure or New York Heart Association (NYHA) Class III or IV

         16. Severe mitral regurgitation

         17. Cardiac transplantation or other cardiac surgery within 12-months of the ablation
             procedure

         18. Unstable angina at the time of the procedure

         19. Acute illness or active systemic infection

         20. AF secondary to non-cardiac or reversible causes

         21. Diagnosed atrial myxoma

         22. Presence of intracardiac defibrillator (ICD) or cardiac resynchronization therapy
             defibrillator (CRT-D)

         23. Significant pulmonary disease that produces chronic symptoms

         24. Significant congenital anomaly or other anatomic or comorbid condition that may impact
             scientific soundness of study

         25. Pregnant or nursing subjects

         26. Enrollment in another study that may interfere with this study

         27. Presence of a condition preventing appropriate vascular access

         28. Life expectancy &lt;12-months

         29. BMI &gt;40 kg/m2

         30. Known sensitivity to contrast media

         31. Renal failure requiring dialysis

         32. Presence of other medical, social, or psychological condition that in the
             investigator's opinion, limits the subject's ability to participate in the study or
             impact the scientific soundness of the study

         33. History of atriotomy or ventriotomy

         34. Implanted left atrial appendage occlusion device
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristin Ruffner</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Louise Yim</last_name>
    <phone>+852 2996 7605</phone>
    <email>louise.yim@abbott.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lori Rusch</last_name>
    <phone>+1 651 756 2668</phone>
    <email>lori.rusch@abbott.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chin Pang Chan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lisie Hospital</name>
      <address>
        <city>Kochi</city>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ajit Thachil</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sejong Hospital</name>
      <address>
        <city>Bucheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sang-Weon Park</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Centre</name>
      <address>
        <city>Soeul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gi-Byoung Nam</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Soeul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kyoung Min Park</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Heart Centre Singapore</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chi Keong Ching</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pipin Kojodjojo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Li-Wei Lo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Phramongkutklao Hospital</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thoranis Chantrarat</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Hong Kong</country>
    <country>India</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
    <country>Taiwan</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 24, 2020</study_first_submitted>
  <study_first_submitted_qc>January 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2020</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Persistent Atrial Fibrillation</keyword>
  <keyword>Radiofrequency Ablation</keyword>
  <keyword>Heart Disease</keyword>
  <keyword>Tachycardia</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Cardiac Conduction System Disease</keyword>
  <keyword>Atrial Fibrillation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

